Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE) have recently come under scrutiny following President Trump’s executive order directing drugmakers to lower medicine prices to match what ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

US pharma major Pfizer (NYSE: PFE) is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a licensing deal worth up to $6 billion for a Chinese-developed drug that ...

New York: Pfizer ... regulatory approvals and 3SBio shareholder approval. Upon close, Pfizer will make a $100 million equity investment in 3SBio subject to an agreed upon securities subscription ...

Donald Trump has signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 ...